Table 11.

Panel of antimicrobial substances, ECOFFs, CBPs and concentration ranges (in mg/L) for Campylobacter jejuni and C. coli

Antimicrobial		ECOFF 2013	CBP 2013	Advised 2012	Decision 2013	ECOFF 2019	CBP 2019	Suggested range, mg/L (no. of wells)
Erythromycin	C. jejuni	4	4	1–128 (8)	1–128 (8)	4	4	1–512 (10)
	C. coli	8	8			8	8
Ciprofloxacin	C. jejuni	0.5	0.5	0.12–16 (8)	0.12–16 (8)	0.5	0.5	0.12–32 (9)
	C. coli	0.5	0.5			0.5	0.5
Tetracycline	C. jejuni	1	2	0.5–64 (8)	0.5–64 (8)	1	1	0.5–64 (8)
	C. coli	2	2			2	2
Streptomycin	C. jejuni	4	NA	1–128 (8)	0.25–16 (7)	4	4
	C. coli	4	NA			4	4
Gentamicin	C. jejuni	2	NA	0.12–16 (8)	0.12–16 (8)	2	2	0.25–16 (7)
	C. coli	2	NA			2	2
Nalidixic acid	C. jejuni	16	NA	–	1–64 (7)	16	16	–
	C. coli	16	NA			16	16
Chloramphenicol	C. jejuni	–	–	–	–	16	16	2–64 (6)
	C. coli	–	–			16	16
Penemsa	C. jejuni	–	–	–	–	–	Ertapenem: 1 (CA‐SFM 2018) Imipenem: 16 (CLSI)b Meropenem: 16 (CLSI)b	Ertapenem: 0.125–4 (6)
	C. coli	–	–	–	–	–	Ertapenem: 1 (CA‐SFM 2018) Imipenem: 16 (CLSI)b Meropenem: 16 (CLSI)b	–

ECOFF: epidemiological cut‐off value; CBP: clinical breakpoint; CLSI: Clinical and Laboratory Standards Institute.

2012: According to EFSA (2012a).

2013: According to Commission Implementing Decision 2013/652/EU.

2019: According to http://mic.eucast.org/Eucast2 (last accessed on 6.3.2019)

CA‐SFM 2018: http://www.sfm-microbiologie.org/UserFiles/files/casfm/CASFM%20V1_0%20FEVRIER%202018.pdf

^ato be chosen among imipenem, meropenem or ertapenem, according to data available in 2019 (QC ranges for the reference strain C. jejuni ATCC 33560, ECOFF values or clinical breakpoints).

^bCLSI breakpoint of 16 mg/L recommended for imipenem and meropenem for other non Enterobacteriaceae by CLSI M100‐S26.